LRG1, a novel serum biomarker for iMCD disease activity

Area of Science:

• Biochemistry
• Immunology
• Proteomics

Background:

• Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder with systemic inflammation and multiorgan dysfunction.
• Current treatment response assessments for iMCD lack sensitivity due to clinical heterogeneity.
• Cytokine storm drives iMCD pathogenesis.

Discussion:

• Proteomic analysis identified Leucine-rich alpha-2-glycoprotein-1 (LRG1) as differentially expressed in iMCD serum samples.
• LRG1 levels decreased significantly with successful treatment, confirmed by ELISA in a larger cohort.
• LRG1 remained elevated in patients with persistent inflammation when CRP was not indicative of disease activity.

Key Insights:

• Serum LRG1 is a sensitive biomarker for assessing treatment response in iMCD.
• LRG1 can indicate ongoing inflammation when C-reactive protein (CRP) levels are misleading.
• The CRP/LRG1 ratio may vary across iMCD subtypes, suggesting distinct inflammatory pathways.

Outlook:

• LRG1 holds potential for monitoring iMCD activity and treatment efficacy.
• Further research into LRG1 may elucidate underlying iMCD disease mechanisms.
• LRG1 could improve patient management and therapeutic strategies for iMCD.